HPTN 083-01

HPTN 083-01 is a clinical trial examining whether injectable cabotegravir (CAB) for PrEP (pre-exposure prophylaxis) is a safe and acceptable method of HIV prevention for adolescents assigned male at birth. HPTN 083-01 is a sub-study of a larger clinical trial called HPTN 083. HPTN 083 examines whether injectable CAB works as PrEP, but in men and transgender women 18 years or older.

This study is a collaboration between the HIV Prevention Trials Network (HPTN), the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN), and ViiV Healthcare.